10-Q: Inhibikase Therapeutics Advances PAH Drug to Phase 2b

Inhibikase Therapeutics reports increased R&D spend and net loss in Q2 2025, driven by its lead PAH program, while maintaining a strong cash position and securing future funding options.

Summary

• Net loss for the three months ended June 30, 2025, increased to $9.9 million from $5.0 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $23.6 million from $9.6 million in the prior year period.
• Research and development (R&D) expenses rose 71.4% to $5.3 million for the three months ended June 30, 2025, and 170.9% to $15.8 million for the six months ended June 30, 2025.
• The six-month R&D increase includes a one-time non-cash charge of $7.4 million for acquired in-process research and development (IPR&D) related to the CorHepta acquisition.
• Selling, general and administrative (SG&A) expenses increased 199.8% to $5.9 million for the three months ended June 30, 2025, and 178.8% to $11.2 million for the six months ended June 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $87.7 million as of June 30, 2025, up from $56.5 million in cash and cash equivalents and $41.1 million in marketable securities as of December 31, 2024.
• The company believes its current cash and equivalents are sufficient to fund operations for at least the next twelve months.
• The lead product candidate, IKT-001 for Pulmonary Arterial Hypertension (PAH), is expected to initiate a Phase 2b clinical study (IMPROVE-PAH) in the second half of 2025.
• The Parkinson's disease program (risvodetinib/IKT-148009) has been discontinued and outlicensed to ABLi Therapeutics, Inc., with potential milestone payments up to $47.5 million and double-digit royalties.
• An Open Market Sale Agreement with Jefferies LLC was established on June 20, 2025, allowing for the sale of up to $200 million in common stock, with no sales made as of June 30, 2025.
• The 2020 Equity Incentive Plan was amended to include an automatic evergreen provision for annual share increases and extend its term to 2030.

Sentiment

Score: 6

Explanation: The company is making significant progress with its lead clinical program (IKT-001 for PAH) entering Phase 2b, supported by a strong cash position for the next 12 months and a substantial new ATM facility for future funding. While losses and expenses have increased, this is typical for a clinical-stage biotech. The strategic outlicensing of the Parkinson's program is a positive for focus. The dilution from increased shares is a trade-off for funding, but the overall outlook for advancing the lead asset is moderately positive.

Positives

• Cash, cash equivalents, and marketable securities increased to $87.7 million as of June 30, 2025, providing an estimated runway of at least twelve months.
• The lead product candidate, IKT-001 for PAH, is progressing to a Phase 2b clinical study (IMPROVE-PAH) in the second half of 2025, a significant development milestone.
• The FDA confirmed the 505(b)(2) pathway for IKT-001, potentially allowing for New Molecular Entity (NME) status and market exclusivity upon approval.
• The Parkinson's disease program (risvodetinib) was strategically outlicensed to ABLi Therapeutics, Inc., reducing internal R&D costs while retaining eligibility for up to $47.5 million in development and regulatory milestones, plus double-digit royalties.
• A recent study published in the American Journal of Respiratory and Critical Care Medicine supports the thesis that imatinib (active ingredient of IKT-001) can be well tolerated and provide strong efficacy in PAH patients.
• The company secured a new Open Market Sale Agreement with Jefferies LLC for up to $200 million, providing significant future capital raising flexibility.

Negatives

• Net loss significantly increased to $9.9 million for the three months and $23.6 million for the six months ended June 30, 2025, compared to prior periods, reflecting higher operating expenses.
• Research and development expenses increased substantially, including a $7.4 million non-cash charge for acquired IPR&D related to the CorHepta acquisition.
• Selling, general and administrative expenses nearly tripled for the three-month period and increased by 178.8% for the six-month period, primarily due to personnel-related costs and stock-based compensation.
• The accumulated deficit grew to $118.0 million as of June 30, 2025, indicating continued historical losses.
• Net cash used in operating activities increased to $9.7 million for the six months ended June 30, 2025, compared to $8.9 million in the prior year, indicating higher cash burn.

Risks

• Healthcare legislative measures, including the Affordable Care Act and Inflation Reduction Act, may adversely affect the business by reducing healthcare costs, imposing price controls, and restricting reimbursement.
• Dependence on third-party manufacturers located in China exposes the company to political, legal, cultural, and trade policy risks, including potential tariffs and data transfer restrictions.
• Changes in U.S. tax law, such as modifications to the capitalization of research and development expenses under Section 174 of the IRC, could adversely affect cash flow and financial condition.
• The company may be unable to raise additional working capital on commercially favorable terms, which would negatively impact its ability to develop product candidates.
• Uncertainty exists regarding the successful development, regulatory approval, and market acceptance of product candidates.
• Competitors may develop new technological innovations that could impact the company's market position.
• The company faces risks related to protecting its proprietary technology.
• The potential for another pandemic, epidemic, or infectious disease outbreak could disrupt business plans, product development activities, clinical trials, and supply chains.

Future Outlook

The company expects to initiate its Phase 2b IMPROVE-PAH clinical study for IKT-001 in the second half of 2025, aiming to assess its efficacy and tolerability in moderate to severe PAH patients. It anticipates increased research and development expenses as it advances its current programs and seeks regulatory approvals. The company also plans to apply for Orphan Drug Designation for IKT-001 for PAH. Future funding needs are expected to be met through a combination of equity offerings, debt financings, and potential collaboration agreements, with a new $200 million ATM facility in place.

Management Comments

• "We expect our research and development expenses to increase for the next several years as we continue to implement our business strategy, advance our current programs, expand our research and development efforts, seek regulatory approvals for any product candidates that successfully complete clinical trials, access and develop additional product candidates and incur expenses associated with hiring additional personnel to support our research and development efforts."
• "We believe that our existing cash, cash equivalents and marketable securities as of June 30, 2025, will enable us to fund our operating requirements for at least the next twelve months following the date of this Quarterly Report."

Industry Context

The global Pulmonary Arterial Hypertension (PAH) market was valued at $7.66 billion in 2023 and is projected to grow at a compound annual growth rate of 5.4% from 2024 to 2030. The recent approval of sotatercept has renewed enthusiasm for anti-proliferative pathways in PAH, aligning with IKT-001's mechanism of inhibiting vascular cell proliferation and fibrosis. The company's strategic decision to outlicense its Parkinson's program reflects a focus on the more promising PAH indication, a common strategy in the biotech industry to optimize resource allocation.

Comparison to Industry Standards

• The company's IKT-001, a prodrug of imatinib, targets the type III receptor tyrosine kinase pathway, offering an alternate mechanism for disease modification in PAH, similar to how sotatercept targets transforming growth factor-beta superfamily ligands.
• A contemporary study confirmed imatinib 100-400mg was well tolerated in WHO Group 1 PAH patients, demonstrating a treatment effect on total pulmonary resistance (TPR) that compares favorably with other novel therapies for PAH, including sotatercept and seralutinib, suggesting competitive efficacy potential.
• The company's pursuit of the 505(b)(2) pathway for IKT-001, which could lead to New Molecular Entity (NME) status and market exclusivity, is a common regulatory strategy for drug developers seeking to leverage existing drug data while securing new intellectual property.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation or legal proceedings.

Related Party Transactions

• During the three and six months ended June 30, 2025, the company did not incur any expenses with a related party vendor.
• As of June 30, 2025, and December 31, 2024, the company had a payable or accrued expense balance with a related party vendor of approximately $0 and $10 thousand, respectively.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future equity raises under the new $200 million ATM facility. Increased R&D spend and clinical trial progression for IKT-001 could lead to long-term value creation if successful. Current net losses and accumulated deficit indicate no near-term dividends.
• **Employees**: Increased personnel-related costs and stock-based compensation, along with amendments to the equity incentive plan, suggest continued investment in employee retention and incentives. Severance costs for former executives indicate past management changes.
• **Customers (Future Patients)**: Advancement of IKT-001 into Phase 2b offers hope for a novel treatment option for Pulmonary Arterial Hypertension, a life-threatening disease.
• **Suppliers/CROs**: Significant new agreements with a clinical trial supply organization ($6.5 million) and a contract research organization ($22.3 million) indicate increased engagement and business for third-party service providers supporting the IMPROVE-PAH study.
• **Creditors**: The company's strong cash position ($87.7 million) and access to additional capital through the ATM facility reduce immediate credit risk, despite recurring losses.

Next Steps

• Initiate the Phase 2b IMPROVE-PAH clinical study for IKT-001 in the second half of 2025.
• Conduct an interim safety review for the IMPROVE-PAH study by the Data Safety Monitoring Board with at least 50 patients at 12-weeks of follow-up.
• Apply for Orphan Drug Designation (ODD) for IKT-001 for PAH once required pre-clinical studies are complete.
• ABLi Therapeutics, Inc. is solely responsible for all further development and commercialization activities of risvodetinib (IKT-148009) under the license agreement.
• The company will continue to evaluate the impact of the One Big Beautiful Bill (OBBB) on its condensed consolidated financial statements.

Key Dates

Recommendation

Inhibikase Therapeutics is at a critical juncture, advancing its lead asset IKT-001 into a Phase 2b trial for PAH, a significant value inflection point for a clinical-stage biotech. The company has a strong cash position for the next 12 months and established a substantial ATM facility for future funding, mitigating immediate liquidity concerns. The strategic outlicensing of the Parkinson's program allows for focused resource allocation. However, the company remains pre-revenue with increasing operating losses and cash burn, typical for its stage. While the clinical progress is positive, the inherent risks of drug development, including trial outcomes and regulatory hurdles, remain high. A 'hold' recommendation is appropriate, acknowledging the promising clinical progress and financial runway, but also the significant execution risks and the need for further data before a more definitive stance can be taken.

Keywords

Pulmonary Arterial Hypertension, PAH, IKT-001, Imatinib, Clinical-stage, Biopharmaceutical, Protein Kinase Inhibitor, Orphan Drug, SEC Filing, 10-Q, Drug Development, Clinical Trials, Biotech, Pharmaceuticals